Determinants of resistance to VEGF-TKI and immune checkpoint inhibitors in metastatic renal cell carcinoma

Table 2 Current updated front line treatment for mRCC based on the IMDC prognostic score risk factors

Front line therapy	Limited Disease Burden/ asymptomatic	Substantial disease burden/ symptomatic
IMDC risk
Good/Favourable risk	Pazopanib^a	Nivolumab^b plus ipilimumab^c
	Sunitinib^a	Pembrolizumab^b plus axitinib^a
		Avelumab^d plus axitinib
Intermediate and poor risk	Nivolumab^b plus ipilimumab^c Pembrolizumab^b plus axitinib^a PD1/PD-L1 immune checkpoint inhibitor contraindications Pazopanib^a, Sunitinib^a, Cabozantinib^a

ISSN: 1756-9966